Lexeo Therapeutics, Inc. Common Stock (LXEO) financial statements and ratios from SEC XBRL: revenue $6.13M (TTM), net margin -1630.7%, revenue growth -18.9% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $6.13M |
| Net Margin | -1630.7% |
| Revenue Growth (YoY) | -18.9% |
| EPS Growth (YoY) | -39.8% |
| FCF Growth (YoY) | 21.2% |
| Price / Book | 1.70 |
| Price / Sales | 50.78 |
| FCF Yield | -20.3% |
| Altman Z-Score | 7.31 (safe) |
| Sector P/E (Healthcare) | 21.7 |
LXEO overview · LXEO earnings · LXEO KPIs · LXEO investor relations · LXEO ownership · LXEO peers · LXEO filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.